Mark A. Velleca Black Diamond Therapeutics, Inc. (BDTX) insider trading activity

Mark A. Velleca is PRESIDENT & CEO of Black Diamond Therapeutics, Inc.. Currently has a direct ownership of 46,522 shares of BDTX, which is worth approximately $122,818. The most recent transaction as insider was on Sep 15, 2023, when has been sold 5,208 shares (Common Stock) at a price of $3.6 per share, resulting in proceeds of $18,748. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 46.5K

0% 3M change

0% 12M change

Total Value Held $122,818

Mark A. Velleca Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Sep 15 2023	BUY Grant, award, or other acquisition	$18,748 $3.6 p/Share	5,208 Added 10.07%	46,522 Common Stock
Jun 16 2023	BUY Grant, award, or other acquisition	$18,750 $2.1 p/Share	8,929 Added 17.77%	41,314 Common Stock
Mar 16 2023	BUY Grant, award, or other acquisition	$18,750 $1.67 p/Share	11,228 Added 25.74%	32,385 Common Stock
Dec 16 2022	BUY Grant, award, or other acquisition	$12,636 $1.5 p/Share	8,424 Added 28.48%	21,157 Common Stock
Sep 16 2022	BUY Grant, award, or other acquisition	$11,250 $2.62 p/Share	4,294 Added 25.22%	12,733 Common Stock
Jun 17 2022	BUY Grant, award, or other acquisition	$11,250 $2.03 p/Share	5,542 Added 39.64%	8,439 Common Stock
Mar 18 2022	BUY Grant, award, or other acquisition	$8,749 $3.02 p/Share	2,897 Added 50.0%	2,897 Common Stock

Also insider at

GTHX

G1 Therapeutics, Inc. Healthcare

MAV

Mark A. Velleca

PRESIDENT & CEO

Research Triangle Park, NC

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells BDTX shares.

Notify only if

Value

Insider Trading

Get notified when an Black Diamond Therapeutics, Inc. insider buys or sells BDTX shares.

Notify only if

Operation

Value

Type

News

Receive news related to Black Diamond Therapeutics, Inc.

Track Activities on BDTX

Account